Continuation of Research and Development Activities
First written in FY2017-Q1. 25 of 34 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Achieved".
- FY2026AchievedAnnual report
「The Company opened the “ARISAWA Innovation Center” in Joetsu, Niigata Prefecture, in September 2025 as a new technology development base for promoting open innovation.」
The ARISAWA Innovation Center, previously described as planned, opened in September 2025. It is positioned as a base for creating and commercializing new technologies through co-creation with external partners, including industry-academia collaboration. - 2026-04-30AdvancedManagement planning
「New customers acquired: 2 companies New themes initiated: 8 (September 2025–March 2026)」
The company reports that its open innovation activities based at the Innovation Center acquired 2 new customers and initiated 8 new themes. - FY2026-H1RestatedAnnual report
「The Group's total research and development expenditure for the current interim consolidated accounting period was ¥1,279 million. There were no significant changes in the status of the Group's research and development activities during the current interim consolidated accounting period.」
Research and development activities continued, with research and development expenses for the current interim consolidated accounting period stated at ¥1,279 million. There were no significant changes in the status of the activities. - FY2025AdvancedAnnual report
「The number of personnel engaged in research and development at the end of the current consolidated fiscal year was 177, and research and development expenses for the current consolidated fiscal year were ¥2,366 million. / The Innovation Center is also scheduled to open in September 2025.」
The disclosure states 177 research and development personnel and research and development expenses of ¥2,366 million, and describes the development of short-time-curing coverlay, 150°C long-term heat-resistant coverlay, environmentally friendly aircraft interior materials and medical 55-inch 4K 3D displays. It also states that the Innovation Center is scheduled to open in September 2025 and that an open innovation environment is being developed to support the process from prototyping through mass production. - FY2025-H1RestatedAnnual report
「The Group's total research and development expenditure for the current interim consolidated accounting period was ¥1,104 million. There were no significant changes in the status of the Group's research and development activities during the current interim consolidated accounting period.」
Research and development activities continued, with research and development expenses for the current interim consolidated accounting period stated at ¥1,104 million. There were no significant changes in the status of the activities. - FY2024-Q3RestatedAnnual report
「The Group's total research and development expenditure for the third quarter of the current consolidated cumulative period was ¥1,520 million. There were no significant changes in the status of the Group's research and development activities during the third quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the third quarter of the current consolidated cumulative period stated at ¥1,520 million. There were no significant changes in the status of the activities. - FY2024-Q2RestatedAnnual report
「The Group's total research and development expenditure for the second quarter of the current consolidated cumulative period was ¥987 million. There were no significant changes in the status of the Group's research and development activities during the second quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the second quarter of the current consolidated cumulative period stated at ¥987 million. There were no significant changes in the status of the activities. - FY2024-Q1RestatedAnnual report
「The Group's total research and development expenditure for the first quarter of the current consolidated cumulative period was ¥464 million. There were no significant changes in the status of the Group's research and development activities during the first quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the first quarter of the current cumulative period stated at ¥464 million. There were no significant changes in the status of the activities. - FY2023-Q3RestatedAnnual report
「The Group's total research and development expenditure for the third quarter of the current consolidated cumulative period was ¥1,451 million. There were no significant changes in the status of the Group's research and development activities during the third quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the third quarter of the current cumulative period stated at ¥1,451 million. There were no significant changes in the status of the activities. - FY2023-Q2RestatedAnnual report
「The Group's total research and development expenditure for the second quarter of the current consolidated cumulative period was ¥907 million. There were no significant changes in the status of the Group's research and development activities during the second quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the second quarter of the current consolidated cumulative period stated at ¥907 million. There were no significant changes in the status of the activities. - FY2023-Q1RestatedAnnual report
「The Group's total research and development expenditure for the first quarter of the current consolidated cumulative period was ¥448 million. There were no significant changes in the status of the Group's research and development activities during the first quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the first quarter of the current cumulative period stated at ¥448 million. There were no significant changes in the status of the activities. - FY2022AdvancedAnnual report
「The number of personnel engaged in research and development at the end of the current consolidated fiscal year was 165, and research and development expenses for the current consolidated fiscal year were ¥1,926 million.」
The disclosure states 165 research and development personnel and research and development expenses of ¥1,926 million, and describes the development and customer evaluation of low-dielectric FPC materials, materials for automotive applications, environmentally friendly honeycomb panels and medical 3D displays. - FY2022-Q3RestatedAnnual report
「The Group's total research and development expenditure for the third quarter of the current consolidated cumulative period was ¥1,421 million. There were no significant changes in the status of the Group's research and development activities during the third quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the third quarter of the current consolidated cumulative period stated at ¥1,421 million. There were no significant changes in the status of the activities. - FY2022-Q2RestatedAnnual report
「The Group's total research and development expenditure for the second quarter of the current consolidated cumulative period was ¥922 million. There were no significant changes in the status of the Group's research and development activities during the second quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the second quarter of the current consolidated cumulative period stated at ¥922 million. There were no significant changes in the status of the activities. - FY2022-Q1RestatedAnnual report
「The Group's total research and development expenditure for the first quarter of the current consolidated cumulative period was ¥439 million. There were no significant changes in the status of the Group's research and development activities during the first quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the first quarter of the current cumulative period stated at ¥439 million. There were no significant changes in the status of the activities. - FY2021AdvancedAnnual report
「Customer certification has already been obtained and sales have begun. / Last year, a fuel-cell component using the Company's proprietary thin-film coating technology was adopted by a Japanese automobile manufacturer, and mass production began. / The Company, together with its consolidated subsidiaries Protec Arisawa Europe, S.A. and Protec Arisawa America, Inc., successfully developed an ultra-high-pressure pressure vessel」
The disclosure describes progress toward commercialization and productization in research and development activities, including customer certification and the start of sales of adhesive sheets, adoption and the start of mass production of fuel-cell components, and the successful development of ultra-high-pressure pressure vessels. - FY2021-Q3RestatedAnnual report
「The Group's total research and development expenditure for the third quarter of the current consolidated cumulative period was ¥1,436 million. There were no significant changes in the status of the Group's research and development activities during the third quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the third-quarter cumulative period stated at ¥1,436 million. There were no significant changes in the status of the activities. - FY2021-Q2RestatedAnnual report
「The Group's total research and development expenditure for the second quarter of the current consolidated cumulative period was ¥971 million. There were no significant changes in the status of the Group's research and development activities during the second quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the second quarter of the current consolidated cumulative period stated at ¥971 million. There were no significant changes in the status of the activities. - FY2021-Q1RestatedAnnual report
「The Group's total research and development expenditure for the first quarter of the current consolidated cumulative period was ¥490 million. There were no significant changes in the status of the Group's research and development activities during the first quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the first quarter of the current cumulative period stated at ¥490 million. There were no significant changes in the status of the activities. - FY2020AdvancedAnnual report
「The number of personnel engaged in research and development at the end of the current consolidated fiscal year was 179, and research and development expenses for the current consolidated fiscal year were ¥2,074 million.」
Research and development personnel totaled 179 and research and development expenses were ¥2,074 million, up from 173 personnel and ¥2,001 million in the previous fiscal year. Results including customer certification evaluations, expanded adoption and successful development in multiple fields were also stated. - FY2020-Q3RestatedAnnual report
「The Group's total research and development expenditure for the third quarter of the current consolidated cumulative period was ¥1,577 million. There were no significant changes in the status of the Group's research and development activities during the third quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the third quarter of the current cumulative period stated at ¥1,577 million. There were no significant changes in the status of the activities. - FY2020-Q2RestatedAnnual report
「The Group's total research and development expenditure for the second quarter of the current consolidated cumulative period was ¥1,032 million. There were no significant changes in the status of the Group's research and development activities during the second quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the second quarter of the current consolidated cumulative period stated at ¥1,032 million. There were no significant changes in the status of the activities. - FY2020-Q1RestatedAnnual report
「The Group's total research and development expenditure for the first quarter of the current consolidated cumulative period was ¥510 million. There were no significant changes in the status of the Group's research and development activities during the first quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the first quarter of the current cumulative period stated at ¥510 million. There were no significant changes in the status of the activities. - FY2019AdvancedAnnual report
「The number of personnel engaged in research and development at the end of the current consolidated fiscal year was 173, and research and development expenses for the current consolidated fiscal year were ¥2,001 million.」
The disclosure states 173 research and development personnel and research and development expenses of ¥2,001 million, as well as specific research results including low-dielectric FPC materials, heat-dissipating adhesive sheets for automobiles, carbon prepreg for aircraft and 55-inch Xpol. - FY2019-Q3RestatedAnnual report
「The Group's total research and development expenditure for the third quarter of the current consolidated cumulative period was ¥1,506 million. There were no significant changes in the status of the Group's research and development activities during the third quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the third quarter of the current cumulative period stated at ¥1,506 million. There were no significant changes in the status of the activities. - FY2019-Q2RestatedAnnual report
「The Group's total research and development expenditure for the second quarter of the current consolidated cumulative period was ¥1,022 million. There were no significant changes in the status of the Group's research and development activities during the second quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the second quarter of the current consolidated cumulative period stated at ¥1,022 million. There were no significant changes in the status of the activities. - FY2019-Q1RestatedAnnual report
「The Group's total research and development expenditure for the first quarter of the current consolidated cumulative period was ¥477 million. There were no significant changes in the status of the Group's research and development activities during the first quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the first quarter of the current cumulative period stated at ¥477 million. There were no significant changes in the status of the activities. - FY2018-Q3RestatedAnnual report
「The Group's total research and development expenditure for the third quarter of the current consolidated cumulative period was ¥1,415 million. There were no significant changes in the status of the Group's research and development activities during the third quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the third quarter of the current cumulative period stated at ¥1,415 million. There were no significant changes in the status of the activities. - FY2018-Q2RestatedAnnual report
「The Group's total research and development expenditure for the second quarter of the current consolidated cumulative period was ¥931 million. There were no significant changes in the status of the Group's research and development activities during the second quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the second quarter of the current consolidated cumulative period stated at ¥931 million. There were no significant changes in the status of the activities. - FY2018-Q1RestatedAnnual report
「The Group's total research and development expenditure for the first quarter of the current consolidated cumulative period was ¥471 million. There were no significant changes in the status of the Group's research and development activities during the first quarter of the current consolidated cumulative period.」
Research and development activities continued, with research and development expenses for the first quarter of the current cumulative period stated at ¥471 million. There were no significant changes in the status of the activities. - FY2017AdvancedAnnual report
「The number of personnel engaged in research and development at the end of the fiscal year was 162, and research and development expenses for the fiscal year were ¥1,756 million.」
Reports 162 research and development employees and research and development expenses of ¥1,756 million. It also describes research outcomes including approval by major users, the start of medical cryostat deliveries and the start of mass production of UV-curable OCA. - FY2017-Q3RestatedAnnual report
「The Group's total research and development expenditure for the third quarter of the current consolidated cumulative period was ¥1,292 million. There were no significant changes in the status of the Group's research and development activities during the third quarter of the current consolidated cumulative period.」
Research and development activities continued, with expenditure for the third quarter of the current cumulative period stated at ¥1,292 million. There were no significant changes in the status of the activities. - FY2017-Q2RestatedAnnual report
「The Group's total research and development expenditure for the second quarter of the current consolidated cumulative period was ¥851 million. There were no significant changes in the status of the Group's research and development activities during the second quarter of the current consolidated cumulative period.」
Research and development activities continued, with expenditure for the second quarter of the current consolidated cumulative period stated at ¥851 million. There were no significant changes in the status of the activities. - FY2017-Q1First statedAnnual report
「The Group's research and development expenses for the nine months ended June 30 were ¥421 million. There were no material changes in the status of the Group's research and development activities during the nine months ended June 30.」
Research and development activities continued, with expenditure of ¥421 million for the cumulative first quarter period. There were no material changes in the status of those activities.